New drug shows promise for rare bone and soft tissue cancers
NCT ID NCT06939855
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called QL1706 in 45 adults with advanced bone or soft tissue sarcoma that cannot be removed by surgery or has spread. Participants receive the drug every 3 weeks. The main goal is to see if the cancer stays stable for at least 12 weeks. Researchers will also monitor side effects and overall response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALVEOLAR SOFT PART SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Tumor-Injected drug combo outlast standard care in advanced sarcoma?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?
- Can a targeted pill stall advanced sarcomas?
- Blood test may spot hidden sarcoma signals
- New pill may keep soft tissue sarcoma in check after chemo
- Immunotherapy boosts chemo against rare sarcomas?